Patients with glaucoma and ocular hypertension ripasudil
Conditions
Interventions
Patients will receive 0.4% ripasudil hydrochloride twice daily for 52 weeks.
Active Comparator Drug
rapasudil
Sponsors
Kowa Company., Ltd
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients who understand the content of the informed consent document of this study and voluntarily give written consent to participate in this study without requiring a proxy 2. Men and women who are 20 years old or older at the time of consent 3. Patients with glaucoma and ocular hypertension who have an inadequate response to other glaucoma medications (such as prostaglandin analogues and beta-blockers) or are unable to use them due to adverse reactions 4. Patients who are able to undergo observation for one year
Exclusion criteria
Exclusion criteria: 1. Patients who have used ripasudil 2. Patients with history of hypersensitivity to any of the components of GLANATEC 3. Patients deemed inappropriate to participate in the study by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intraocular pressure Visit 1 (Week 0) Visit 2 (Week 12) and Visit 3 (Week 52) mmHg,Adverse events Continuously after starting ripasudil treatment - | — |
Secondary
| Measure | Time frame |
|---|---|
| Central corneal thickness Visit 1 (Week 0) Visit 2 (Week 12) and Visit 3 (Week 52) are optional. micron,Corneal endothelial cell density Visit 1 (Week 0) Visit 2 (Week 12) and Visit 3 (Week 52) are optional. cells/mm2 | — |
Countries
Thailand
Contacts
Public Contactkulawan rojananuangnit
Mettapracharak Hospital
Outcome results
None listed